Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Home > Our Company

About Spectrum Pharmaceuticals

Spectrum Pharmaceuticals is a commercial-stage biotechnology Company with fully integrated commercial and drug development operations, and a leader in hematology/oncology.

Our primary strategy is comprised of acquiring, developing and commercializing a broad and diverse pipeline of late-stage clinical and commercial products.

Spectrum has three drugs in advanced development:

  • Poziotinib for patients with a mutation in Non Small Cell Lung Cancer (NSCLC), and for patients with breast cancer.
  • Eflapegrastim, being developed for chemotherapy-induced neutropenia in patients with breast cancer.
  • Apaziquone for Intravesical Instillation, being developed for immediate intravesical instillation post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer.
In addition to an efficient in-house clinical development organization with regulatory and data management capabilities, Spectrum has established a commercial infrastructure for its marketed products. Currently, we have six oncology/hematology products on the market that target different types of non-Hodgkin's lymphoma, advanced metastatic colorectal cancer, a type of acute lymphoblastic leukemia (ALL) and multiple myeloma.

Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Careers at Spectrum

Visit our careers page to learn about new job opportunities and how to become a part of the Spectrum team.


The Key is our People

Collectively, the members of our team have relevant experience in both the development and marketing of oncology drugs and the growth of profitable business ventures.

Spectrum Pharmaceuticals trade show booth

Our passion to identify, develop and deliver important options for patients suffering from cancer is behind every action we take. At Spectrum, we are committed to excellence and strive to make a difference in the lives of patients every day.

Our Goal is to Bring Quality Drugs to Patients

Spectrum Pharmaceuticals actively seeks and evaluates potentially important drug candidates. Once we identify these candidates, we rapidly assess preclinical and clinical data, and the commercialization potential of candidates. Then through both in-licensing and co-development partnerships, we provide the expertise and neccesary funding to bring the most promising products through the complex development process to market.

In order to maximize the commercial potential of our current and future drugs, Spectrum has assembled a distinguished Commercial Team that was recruited from the top sales performers in the oncology specialty arena, and who are dedicated to bringing important, quality treatments to cancer patients.

Spectrum's Code of Conduct

At Spectrum:

  1. We will use all lawful and ethical means possible to bring our therapy options to the right patients, in the right way.
  2. We will be personally responsible to understand and adhere to the letter and spirit of all laws and Company policies that pertain to our daily business.
  3. We will partner only with healthcare professionals, suppliers, and other business partners who share our commitment to understand and uphold the laws and regulations that apply to our operations.
  4. We will respect and protect the dignity and privacy of patients, healthcare professionals and their staff, business partners, competitors, and our fellow employees.
  5. We will promptly and cooperatively report without fear of retaliation any behavior contrary to these principles to management, the Compliance Department, or the compliance helpline.

You may contact Spectrum's Compliance Officer at any time at: compliance@sppirx.com

  • Click here to view a PDF of Spectrum's Notice of Compliance.
  • Click here to view a PDF of Spectrum's Compliance Program.
  • Click here to view a PDF of Spectrum's Code of Business Conduct and Ethics.

Back to top